KTS002 / Kodikaz - LARVOL DELTA

Zip-code drug conjugates (ZDCs): Ctdna-guided therapy shows strong efficacy and low toxicity in vitro and In Vivo (ASH 2025) - "Compared to Belantamab (an anti-BCMA MM ADC), KTS002 was 1000-fold more cytotoxic in cells with p53 deletions or mutations...In MM1Sxenograft models, KTS002 demonstrated dose-dependent tumor suppression, with high-dose treatmentoutperforming bortezomib...KTS002 is a promising new therapy for MM, especially in high-risk patients, offering strongefficacy with minimal toxicity. Ongoing studies are focused on dose optimization, pharmacokinetics, andsafety to support IND-enabling and clinical development."

Circulating tumor DNA • IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • FGFR3 • MAFB • NSD2